$A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma$

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma

Panobinostat is a histone deacetylase inhibitor that has shown synergistic preclinical anti-myeloma activity when combined with other agents, recently exhibiting synergy with the alkylating agent melphalan (Sanchez et al., Leuk Res 35(3):373–379, 2011 ). This phase 1/2 trial investigated the safety...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of hematology 2014, Vol.93 (1), p.89-98
Hauptverfasser:	Berenson, James R., Hilger, James D., Yellin, Ori, Boccia, Ralph V., Matous, Jeffrey, Dressler, Kenneth, Ghazal, Hassan H., Jamshed, Saad, Kingsley, Edwin C., Harb, Wael A., Noga, Stephen J., Nassir, Youram, Swift, Regina A., Vescio, Robert
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Disease Progression Dose-Response Relationship, Drug Drug Administration Schedule Female Gastrointestinal Diseases - chemically induced Hematologic Diseases - chemically induced Hematology Humans Hydroxamic Acids - administration & dosage Hydroxamic Acids - adverse effects Indoles - administration & dosage Indoles - adverse effects Infection - etiology Kaplan-Meier Estimate Male Maximum Tolerated Dose Medicine Medicine & Public Health Melphalan - administration & dosage Melphalan - adverse effects Middle Aged Multiple Myeloma - drug therapy Oncology Recurrence Review Article Salvage Therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!